lithiumlogo.jpg
Standard Lithium Reports Fiscal First Quarter 2023 Results, Achieves Key Project Milestones Towards Commercialization
November 10, 2022 07:05 ET | Standard Lithium
VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE: SLI) (FRA: S5L), a leading pre-commercial lithium...
GeoJunxion NV (ticker: GOJXN.AS) - Financial & Business update Q1 (July - September) 2022/23
November 10, 2022 02:00 ET | GeoJunxion N.V.
Key Facts: 102% revenue growth for Q1 2022/23 compared to the same period in 2021/22;10% reduction in Net Operational Expenses (OPEX) for Q1 2022/23 compared to the same period in 2021/22;EBITDA and...
GeoJunxion NV (ticker: GOJXN.AS) - Financiële en Operationele update 1ste kwartaal 2022-23 (juli - september)
November 10, 2022 02:00 ET | GeoJunxion N.V.
Belanrijkste punten: 102% omzetgroei voor Q1 2022/23 in vergelijking met dezelfde periode in 2021/22;10% verlaging van de netto operationele kosten (OPEX) voor Q1 2022/23 t.o.v. dezelfde periode in...
Esperion Logo (primary).png
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
November 01, 2022 07:00 ET | Esperion Therapeutics, Inc.
– CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion – – Remain On Track to Report Topline Results in January 2023, with Full Results Targeted to be...
Esperion Logo (primary).png
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
October 17, 2022 08:02 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on...
Esperion Logo (primary).png
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
August 02, 2022 07:00 ET | Esperion Therapeutics, Inc.
– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and...
Arbutus Biopharma Logo
Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
January 24, 2022 07:30 ET | Arbutus Biopharma Corporation
Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for...
VIR_logo_large.jpg
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 05, 2021 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. ...
VIR_logo_large.jpg
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
July 22, 2021 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter...
5ProductsLogo.png
Data443 CEO Enhances Capital Structure of Company Through Transactions Involving Its Convertible Debt Obligations
January 29, 2020 15:29 ET | DATA443 Risk Mitigation Inc.
RALEIGH, N.C., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Mr. Jason Remillard, the Founder and CEO of Data443 Risk Mitigation, Inc. (OTCPK: ATDS), a leading data security and privacy software company, has...